What is Charles River Laboratories's market cap?

Charles River Laboratories (CRL) has a market capitalization of $10.8B and trades on NYSE.

What is Charles River Laboratories's revenue and profitability?

Charles River Laboratories generated $4.0B in trailing twelve-month revenue with a net loss of $184.7M, representing a net margin of -4.6%. Gross margin stands at 84.7%, with free cash flow of $391.3M. These figures are based on the Q1 2026 filing.

Who are Charles River Laboratories's competitors?

Charles River Laboratories's key competitors include Labcorp, Champions Oncology, Inc., IQVIA Holdings Inc., and others. These companies compete in similar markets and product categories.

Who does Charles River Laboratories partner with?

Charles River Laboratories's notable partners include Venture Capital Firms.

What subsidiaries does Charles River Laboratories have?

Charles River Laboratories's subsidiaries include Explora BioLabs, Noveprim, K.F. (Cambodia) Ltd..

Where is Charles River Laboratories headquartered?

Charles River Laboratories is headquartered in United States of America and employs approximately 21,400 people. It has been publicly traded since 2000.

Charles River Laboratories

CRL

Market cap

$10.79B+39.8%

Revenue$4.0B+0.1%

Net income-$184.7M-170%

Free cash flow$391.3M-30.5%

EPS (diluted)-$3.70-176%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$995.8MBeat by $18.4M EPS$2.06Beat by $0.10

Read the full report

Next report

Aug 5, 2026 (In 3 weeks)

Revenue estimate$976.1M

EPS estimate$2.72

Financials

Q1 2026

Income statement

See full

Revenue$995.8M+1.2%

Operating income$119.9M+60.6%

Net income-$14.8M-158%

EPS (diluted)-$0.30-160%

Balance sheet

See full

Cash & equivalents$198.2M-14.5%

Total debt$3.1B+1.9%

Total equity$2.9B-7.9%

Total assets$7.7B+2.0%

Cash flow

See full

Operating cash flow$41.1M-76.1%

CapEx$55.9M-5.8%

Free cash flow-$14.8M-113%

Valuation & ratios

Valuation

See full

Market cap$10.79B+39.8%

Enterprise value$13.66B+32.0%

P/S2.7×+0.8×

Profitability

See full

Net margin-4.6%—

FCF margin9.7%-4.3pp

Returns & leverage

See full

Return on equity-6%—

Debt / equity1×+0.1×

Current ratio1.4×-0.1×

Segments

By segment

See full

DSA$596.9M+0.7%

RMS$208.4M-2.2%

Manufacturing$190.5M+6.8%

By geography

See full

Europe$277.6M+5.4%

Asia Pacific$55.5M+32.3%

Other$9.4M-43.6%

By product

See full

Cost of services provided (excluding amortization of intangible assets)$798.2M0.0%

Competitors

By market cap

IQVIA$34.0B+19.7%

Labcorp Holdings$22.8B+3.9%

Revvity$12.2B+2.2%

Charles River Laboratories$10.8B+39.8%

Ginkgo Bioworks$592.5M-20.4%

CMI

Columbus Circle Capital Corp II $317.4M—

Rapid Micro Biosystems$85.7M-46.1%

Champions Oncology$84.2M-20.7%

By revenue growth

Rapid Micro Biosystems+16.0%

Labcorp Holdings+7.3%

IQVIA+7.3%

Revvity+4.8%

Charles River Laboratories+0.1%

Ginkgo Bioworks-37.8%

By net margin

IQVIA8.33%-0.3pp

Revvity8.26%-2.1pp

Labcorp Holdings6.66%+1.1pp

Charles River Laboratories-4.59%-11.1pp

Rapid Micro Biosystems-145.81%+5.4pp

Ginkgo Bioworks-215.41%-7.7pp

Profile

Charles River Laboratories is a leading global provider of non-clinical drug development products and services, supporting the pharmaceutical and biotechnology industries from target identification through manufacturing. The company offers a comprehensive portfolio of research models, discovery services, and safety assessment tools designed to accelerate drug research and improve speed to market. Its core value proposition lies in providing an integrated, full-service outsourcing model that reduces costs and enhances productivity for life science organizations.

Competitive position

Charles River is the largest provider of outsourced drug discovery and regulated safety testing services worldwide, maintaining a leading position in laboratory animal medicine.

GeographiesNorth America, Europe, Asia, Canada

Customer segmentsPharmaceutical Companies, Biotechnology Companies, Academic and Government Institutions, Medical Device Manufacturers

Business modelContract Research Organization (CRO), Contract Development and Manufacturing Organization (CDMO), Product Sales, Professional Services

SuppliersNon-human primate suppliers, Horseshoe crab harvesters, Specialized laboratory equipment manufacturers, Human cell donors

CustomersGlobal pharmaceutical firms, Emerging biotech startups, Agrochemical and industrial chemical companies, Clinical trial sponsors

CountryUnited States of America

Listed2000

Employees21.4K

CEOJames C. Foster

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websitecriver.com

FilingsSEC EDGAR

Ask your AI about Charles River Laboratories.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Charles River Laboratories's market cap?: Charles River Laboratories (CRL) has a market capitalization of $10.8B and trades on NYSE.
What is Charles River Laboratories's revenue and profitability?: Charles River Laboratories generated $4.0B in trailing twelve-month revenue with a net loss of $184.7M, representing a net margin of -4.6%. Gross margin stands at 84.7%, with free cash flow of $391.3M. These figures are based on the Q1 2026 filing.
Who are Charles River Laboratories's competitors?: Charles River Laboratories's key competitors include Labcorp, Champions Oncology, Inc., IQVIA Holdings Inc., and others. These companies compete in similar markets and product categories.
Who does Charles River Laboratories partner with?: Charles River Laboratories's notable partners include Venture Capital Firms.
What subsidiaries does Charles River Laboratories have?: Charles River Laboratories's subsidiaries include Explora BioLabs, Noveprim, K.F. (Cambodia) Ltd..
Where is Charles River Laboratories headquartered?: Charles River Laboratories is headquartered in United States of America and employs approximately 21,400 people. It has been publicly traded since 2000.